MedPath

MethylGene Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

Phase 2
Completed
Conditions
Vulvovaginal Candidiasis
Interventions
First Posted Date
2011-12-22
Last Posted Date
2013-04-04
Lead Sponsor
MethylGene Inc.
Target Recruit Count
220
Registration Number
NCT01497223
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Women's Health Care Research Corp., San Diego, California, United States

🇺🇸

Altus Research, Lake Worth, Florida, United States

and more 15 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.